Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12955285rdf:typepubmed:Citationlld:pubmed
pubmed-article:12955285lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0007776lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0022655lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0001613lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0333051lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0681797lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:12955285lifeskim:mentionsumls-concept:C0598695lld:lifeskim
pubmed-article:12955285pubmed:issue3-4lld:pubmed
pubmed-article:12955285pubmed:dateCreated2003-10-7lld:pubmed
pubmed-article:12955285pubmed:abstractTextThere is an urgent need to improve the pharmacotherapy of schizophrenia despite the introduction of important new medications. New treatment insights may come from appreciating the therapeutic implications of model psychoses. In particular, basic and clinical studies have employed the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, as a probe of NMDA receptor contributions to cognition and behavior. These studies illustrate a translational neuroscience approach for probing mechanistic hypotheses related to the neurobiology and treatment of schizophrenia and other disorders. Two particular pathophysiologic themes associated with schizophrenia, the disturbance of cortical connectivity and the disinhibition of glutamatergic activity may be modeled by the administration of NMDA receptor antagonists. The purpose of this review is to consider the possibility that agents that attenuate these two components of NMDA receptor antagonist response may play complementary roles in the treatment of schizophrenia.lld:pubmed
pubmed-article:12955285pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:languageenglld:pubmed
pubmed-article:12955285pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:citationSubsetIMlld:pubmed
pubmed-article:12955285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12955285pubmed:statusMEDLINElld:pubmed
pubmed-article:12955285pubmed:monthSeplld:pubmed
pubmed-article:12955285pubmed:issn0033-3158lld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:KrystalJohn...lld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:D'SouzaD...lld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:PerryEdwardElld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:MathalonDanie...lld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:BelgerAysenil...lld:pubmed
pubmed-article:12955285pubmed:authorpubmed-author:HoffmanRalphRlld:pubmed
pubmed-article:12955285pubmed:issnTypePrintlld:pubmed
pubmed-article:12955285pubmed:volume169lld:pubmed
pubmed-article:12955285pubmed:ownerNLMlld:pubmed
pubmed-article:12955285pubmed:authorsCompleteYlld:pubmed
pubmed-article:12955285pubmed:pagination215-33lld:pubmed
pubmed-article:12955285pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:meshHeadingpubmed-meshheading:12955285...lld:pubmed
pubmed-article:12955285pubmed:year2003lld:pubmed
pubmed-article:12955285pubmed:articleTitleNMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.lld:pubmed
pubmed-article:12955285pubmed:affiliationSchizophrenia Biological Research Center (116-A), VA Connecticut Healthcare System, 950 Campbell Ave., West Haven, CT 06516, USA. john.krystal@yale.edulld:pubmed
pubmed-article:12955285pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12955285pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12955285pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:12955285pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12955285lld:pubmed